Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Role Of Sensitivity to neuroEndocrine Systems in Social Decisions

NCT06018727
Conditions
Borderline Personality Disorder
Interventions
Hydrocortisone, Yohimbine, Placebo
Drug · Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Not yet recruiting Phase 4 Interventional

Opzelura Experience Study

NCT07661979
Conditions
Atopic Dermatitis
Interventions
ruxolitinib, ruxolitinib and an Eczema Action Plan
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Infectious Disease
Interventions
Visualization tool
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Atopic Dermatitis
Interventions
Wrist Actigraphy Devices, Polysomnography, Videography
Device
Lead sponsor
Boston University
Other
Eligibility
2 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

Childhood Allergy and the Neonatal Environment

NCT04215783
Conditions
Asthma in Children, Allergy
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Nashville, Tennessee + 1 more
Conditions
Asthma
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Long Beach, California • Medford, Oregon
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Blood-based Biomarkers of Asthma

NCT00917787
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Conditions
Allergies, Food Allergy
Interventions
5mg/kg omalizumab injection, 15mg/kg omalizumab injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Dallas, Texas
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Technosphere® Insulin, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Mission Hills, California • San Diego, California • Palm Harbor, Florida + 8 more
Conditions
Asthma
Interventions
CareTRx
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Conditions
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Interventions
dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions
Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 69 more
Conditions
Allergy
Interventions
Xolair (omalizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Completed Not applicable Interventional Accepts healthy volunteers Results available

Stress and the Nervous System

NCT02339506
Conditions
Autonomic Nervous System, Baroreflex, Stress, Physiological
Interventions
Cosyntropin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Efficacy and Safety Study in Subjects With Asthma

NCT00980200
Conditions
Asthma
Interventions
Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Genetic Factors in the Development of Lung Disease

NCT00001532
Conditions
Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma, Pulmonary Sarcoidosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Atopic Dermatitis
Interventions
Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more
Conditions
Asthma
Interventions
BDA MDI, AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
113
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 91 more
Conditions
Hypersensitivity Pneumonitis, Chronic Hypersensitivity Pneumonitis, Interstitial Lung Disease, Extrinsic Allergic Alveolitis, Health-related Quality of Life
Interventions
Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Asthma
Interventions
MSTT1041A, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 37 more